The DMARDs include non-biologic (e.g. methotrexate) and biologic agents (TNF-α inhibitor drugs and non TNF-α biologics) that halt the progression of RA by reducing inflammation, preventing joint damage and maintaining the integrity of joints [1]. Here, TNF is linked to rheumatoid arthritis.